Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy-Reference-Cited by-同舟云学术

Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy

Published:2012-07-07 Issue:1 Volume:7 Page:162-170
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Chen Chun-Hao,Huang Jee-Fu,Huang Chung-Feng,Yeh Ming-Lun,Yang Jeng-Fu,Hsieh Ming-Yen,Hou Nai-Jen,Lin Zu-Yau,Chen Shinn-Cherng,Hsieh Ming-Yuh,Wang Liang-Yen,Chuang Wan-Long,Dai Chia-Yen,Yu Ming-Lung

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

http://link.springer.com/content/pdf/10.1007/s12072-012-9388-x.pdf

Reference32 articles.

1. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009;24:336–345

2. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008;47:1884–1893

3. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553–559

4. Hung CH, Lee CM, Lu SN, et al. Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy? J Gastroenterol Hepatol 2002;17:1307–1311

5. Lau JY, Mizokami M, Ohno T, et al. Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet 1993;342:1208–1209

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD;Hepatology International;2024-08-08

2. Fatty liver and viral hepatitis: Prevalence, risk factors, natural course, pathogenesis, and management;Metabolic Steatotic Liver Disease;2024

3. Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases;Clinical and Molecular Hepatology;2023-01-01

4. Residual risk of liver disease after hepatitis C virus eradication;Journal of Hepatology;2021-04

5. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs;Liver International;2019-07-25